When a patient undergoes surgery for head and neck cancer, the biggest worry is whether any hidden cells remain. New research looks at a tool called ctDNA, which are fragments of cancer DNA that circulate in the blood. For patients with HPV-negative head and neck cancer, finding these fragments after surgery was linked to a much higher risk of the cancer coming back.
Researchers looked at data from 325 patients. They found that those with detectable ctDNA in their blood after surgery had significantly lower rates of survival and were more likely to see their cancer return. However, the data comes from a small group of patients and uses different testing methods, which makes the results less certain.
Because the evidence is still preliminary, doctors do not yet use this as a standard tool. The study shows a strong link between blood markers and cancer recurrence, but more large and consistent studies are needed before this can be used in everyday clinical practice.
Common questions
What is ctDNA and how does it work?
ctDNA stands for circulating tumor DNA. These are small pieces of DNA from cancer cells that enter the bloodstream. In this study, researchers looked at these fragments in the blood of 325 patients after they had surgery for head and neck cancer to see if they could predict if the cancer would return.
Can this test tell if my cancer will come back?
The study found that detectable ctDNA after surgery was associated with a higher risk of cancer returning and lower overall survival. However, the evidence is still preliminary. Because of small sample sizes and different testing methods, doctors cannot use it as a confirmed tool just yet.
Is this test currently used in clinics?
No, ctDNA is still considered an investigational marker. While the study showed a strong link between detectable DNA and cancer recurrence, more large and multi-institution studies are needed before it can be used as a standard part of cancer treatment.
